miR-21-3p and miR-192-5p in patients with type 2 diabetic nephropathy
- PMID: 35976169
- DOI: 10.1515/dx-2022-0036
miR-21-3p and miR-192-5p in patients with type 2 diabetic nephropathy
Abstract
Objectives: Microribonucleic acids (microRNA/miRNA/miR-) are predicted to be useful in the early diagnosis, monitoring, and treatment of diabetic nephropathy (DN). We aimed to investigate the relationship of DN to miR-21-3p, miR-29a-3p, miR-29b-3p, miR-29c-3p, miR-126-3p, miR-129-1-3p, miR-137, miR-192-5p, miR-212-3p, and miR-320c.
Methods: There were 50 healthy controls and 100 patients with type 2 diabetes mellitus (T2DM). The diabetic patients were divided into three subgroups: normal to mildly increased (A1, n=51), moderately increased (A2, n=25), and severely increased (A3, n=24) albuminuria. The biochemical measurements were analysed using Roche Cobas 8000. The plasma miRNAs were analysed using RT-qPCR based on SYBR green chemistry.
Results: The relative expression of miR-21-3p was significantly lower in the (A3 p=0.005, 6.6-fold decrease) and DN (A1 + A3) (p=0.005, 6.6-fold decrease) groups compared to the controls. The relative expression of miR-192-5p was also significantly lower in the DN group (p=0.027, 2.4-fold decrease) compared to the controls. The area under curve value was 0.726 for miR-21-3p and 0.717 for miR-192-5p for distinguishing the DN group from the controls.
Conclusions: The decreased expressions of miR-21-3p and miR-192-5p are associated with the development of DN and may be potential biomarkers for the early diagnosis of DN.
Keywords: circulating microRNAs; diabetes mellitus; diabetic nephropathy.
© 2022 Walter de Gruyter GmbH, Berlin/Boston.
References
-
- World Health Organization . Global report on diabetes . Geneva, Switzerland: World Health Organization; 2016978–88 p.
-
- KDIGO CKD Work Group . Kidney Disease: improving Global Outcomes (KDIGO) 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1–136.
-
- Diabetes Canada Clinical Practice Guidelines Expert Committee . Diabetes Canada 2018 clinical practice guidelines for the prevention and management of Diabetes in Canada. Can J Diabetes 2018;42:1–342.
-
- Simpson, K, Wonnacott, A, Fraser, DJ, Bowen, T. MicroRNAs in diabetic nephropathy: from Biomarkers to therapy. Curr Diabetes Rep 2016;16:1–7. https://doi.org/10.1007/s11892-016-0724-8 . - DOI
-
- Jonas, S, Izaurralde, E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet 2015;16:421–33. https://doi.org/10.1038/nrg3965 . - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical